BRD4-binding enhancer promotes CRC progression by interacting with YY1 to activate the Wnt pathway through upregulation of TCF7L2

• DOI: 10.1016/j.bcp.2023.115877
• Publication Date: 2023-10-23T05:36:42Z
• Authors: Biao Duan; Xuwei Zhou; Xiaoyi Zhang; Fenglan Qiu; Shaoqing Zhang; Yue Chen; Jun Yang; Juan Wang; Wenfu Tan
• Keywords: Gene Expression Regulation, Neoplastic; Cell Line, Tumor; Humans; Nuclear Proteins; Cell Cycle Proteins; Colorectal Neoplasms; Transcription Factor 7-Like 2 Protein; Wnt Signaling Pathway; 3. Good health; Cell Proliferation; Epigenesis, Genetic; Transcription Factors; Up-Regulation

Colorectal carcinoma (CRC), one of the most life-threatening cancer types, is associated with aberrant expression of epigenetic modifiers and activation of the Wnt pathway. However, the role of epigenetic regulators in driving cancer cell proliferation and their potential as therapeutic targets affecting the Wnt pathway remain unclear. In this study, BRD4 was found to promote the progression of CRC both in vitro and in vivo. The expression of BRD4 correlated with shortened CRC patient survival. In addition, BRD4 function was strongly correlated with the Wnt pathway, but rather through regulation of TCF7L2 at transcriptional levels. BRD4 and H3K27ac have overlapping occupancies in the cis-regulatory elements of TCF7L2, suggesting enhancer-based epigenetic regulation. Numerous YY1 binding sites were found in the abovementioned region. YY1 recruited BRD4 to bind to cis-regulatory elements of TCF7L2, thereby regulating the expression of TCF7L2. Altogether, this study validates that BRD4 performs a canonical epigenetic regulatory function in CRC and can be used in the treatment of Wnt pathway-dependent CRC or other malignancies with clinically available bromodomain inhibitors.